Archives
-
Glutamine Metabolism and Liver Fibrosis in HSCs
2026-10-06
Yin and colleagues identify SIRT4–GDH regulation as a metabolic mechanism that constrains hepatic stellate cell activation and liver fibrosis. Their in vitro and in vivo evidence supports glutamine catabolism as a therapeutic research direction, while also showing why metabolic viability readouts should be interpreted alongside pathway-specific and fibrosis-related endpoints.
-
Dual-Action Inhibitors and p38α Dephosphorylation
2026-10-06
A 2024 bioRxiv preprint reports that selected kinase inhibitors can both inhibit p38α activity and accelerate removal of its activation-loop phosphate by WIP1. The work introduces a structure-guided concept for kinase regulation, while its implications for cytokine production, inflammatory disease, and myelodysplastic syndromes research remain to be established.
-
Angiotensin Peptides and SARS-CoV-2 Spike Binding
2026-10-05
A 2025 study reports that several naturally occurring angiotensin peptides enhance binding between the SARS-CoV-2 spike protein and host receptors, with the strongest effects observed for shorter N-terminally modified fragments. The findings identify a potential molecular connection between renin-angiotensin signaling and viral receptor recognition, while remaining limited to in vitro binding evidence rather than clinical or infection outcomes.
-
Z-YVAD-FMK and the Logic of Pyroptosis Evidence
2026-10-05
Z-YVAD-FMK is a cell-permeable caspase-1 inhibitor for distinguishing pyroptotic signaling from overlapping death programs. This article examines how it can strengthen causal interpretation of the HOXC8–CASP1 axis while clarifying evidence limits, model boundaries, and assay interpretation.
-
Angiotensin 1/2 (1-6) Research Overview
2026-10-04
A source-grounded overview of Angiotensin 1/2 (1-6), covering renin–angiotensin system context, reported spike-protein binding findings, cardiovascular and renal research relevance, evidence strength, and key limitations.
-
Sulfo-NHS-SS-Biotin in Kir7.1 Surface Studies
2026-10-03
Sulfo-NHS-SS-Biotin is a cleavable, amine-reactive labeling reagent that can conceptually support studies of membrane-protein abundance and trafficking. In the Kir7.1 literature, however, the strongest evidence concerns glycosylation, surface expression, and channel activity—not reagent-specific performance—so conclusions about Sulfo-NHS-SS-Biotin should remain bounded by the available sources.
-
BFH772 (VEGFR2 inhibitor) Workflow Guide
2026-10-02
BFH772 is a selective small-molecule VEGFR2 inhibitor for controlled kinase, cellular angiogenesis, and tumor-model studies where organic-solvent formulation is acceptable. It should not be treated as a broad-spectrum kinase inhibitor or used in workflows that require water solubility without assay-specific formulation and precipitation controls.
-
Homoharringtonine Against SARS-CoV-2: Study Analysis
2026-10-01
The reference study connects homoharringtonine’s ribosome-directed inhibition of protein elongation with broad coronavirus suppression, rapid viral clearance in a mouse model, and exploratory observations in treated patients. Its main practical contribution is a testable upper-respiratory-tract strategy, although the clinical evidence remains preliminary and requires controlled validation.
-
Ferrostatin-1 (Fer-1): Mechanism and Assay Use
2026-10-01
Ferrostatin-1 (Fer-1) is a selective ferroptosis inhibitor that suppresses lipid reactive oxygen species and lipid peroxidation. Its reported cellular EC50 of approximately 60 nM supports use as a mechanistic rescue control in ferroptosis assays, while product-specific solubility and storage conditions should guide experimental preparation.
-
D-Luciferin for BLI in Glioblastoma Research
2026-09-30
D-Luciferin potassium salt enables real-time, non-invasive tracking of luciferase-labeled tumor cells and treatment response in preclinical models. This guide connects reliable BLI workflows with the macrophage membrane-camouflaged nanoparticle strategy reported for glioblastoma, while separating optical viability measurements from nanoparticle biodistribution.
-
Lisinopril Dihydrate: Assay Logic
2026-09-30
Lisinopril dihydrate is a long-acting ACE inhibitor whose value extends beyond blood-pressure models. This article explains how to use it as an interpretable mechanistic probe, integrating product chemistry with comparative peptidase evidence and assay-design decisions.
-
Honokiol Workflows for Better Cancer Assays
2026-09-29
Honokiol can be evaluated as an NF-κB pathway inhibitor, antioxidant, and antiangiogenic research compound—but only if growth arrest and cell killing are measured separately. This workflow combines controlled solvent handling, time-resolved viability testing, ROS readouts, and orthogonal validation for more interpretable cancer and inflammation studies.
-
Angiotensin II: Practical Research Workflow
2026-09-29
This guide explains how to use Angiotensin II as a controlled receptor agonist for vascular signaling, oxidative-stress, and remodeling workflows. It provides product-dossier starting conditions for cell and animal studies, but it is not a substitute for study-specific optimization, validated disease protocols, or diagnostic or medical use.
-
Electrical Stimulation Boosts Nanoparticle Endocytosis
2026-09-28
The reference study demonstrates that alternating-current electrical stimulation can enhance magnetic nanoparticle uptake by cancer cells without requiring particle-surface functionalization. Its combination of uptake quantification, imaging, cytoskeletal analysis, and functional magnetic hyperthermia and MRI assays links a macropinocytic mechanism to improved biomedical performance.
-
ATRX Loss Sensitizes Glioma Cells to RTK Inhibitors
2026-09-28
A 2022 drug-screening study found that ATRX-deficient high-grade glioma cells were more sensitive to several receptor tyrosine kinase and PDGFR inhibitors than comparator cells. It also reported pronounced toxicity when selected RTK inhibitors were combined with temozolomide, supporting ATRX status as a relevant variable for preclinical studies and clinical-trial analyses—not as a validated treatment-selection rule.